Merck: FDA approves melanoma treatment

(CercleFinance.com) - Merck announced on Friday evening that the US FDA has approved its Keytruda immunotherapy for patients with melanoma.


The green light from the US health authority is for the post-operative treatment of adults and children over 12 years of age with stage IIB or IIC skin cancer after removal of their tumour, the US laboratory said.

In phase 3 clinical trials, the administration of Keytruda resulted in a 35% reduction in the risk of disease recurrence or death compared to placebo, it added.


Copyright (c) 2021 CercleFinance.com. All rights reserved.